EuroPCR

EuroPCR

May 24, 2013
3 min read
Save

BP reductions with EnligHTN ablation system sustained at 1 year

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PARIS — New 6-month and 1-year data from the EnligHTN I first-in-man study demonstrate safety and efficacy of the multielectrode renal denervation system in patients with drug-resistant hypertension.

The prospective, multicenter, feasibility EngligHTN I trial enrolled 46 patients (mean age, 60 years; mean BMI, 32) who were taking at least three antihypertensive medications including a diuretic. Mean baseline BP was 176 mm Hg/96 mm Hg.

According to 1-year data presented at EuroPCR, patients treated with the EnligHTN Renal Denervation System (St. Jude Medical) experienced a mean systolic BP reduction of –27 mm Hg points when measured in an office setting. Further, 80% of patients responded to therapy, defined as BP reduction ≥10 mm Hg when measured during an office visit. The researchers reported no significant changes in kidney function, according to a company press release.

“The results of the EnligHTN I study confirm that the early significant reduction in BP is sustained through 12 months, but as important are the favorable renal effects as evidenced by an improvement in some kidney markers,” primary investigator Stephen G. Worthley, MBBS, PhD, of Royal Adelaide Hospital in Australia, stated in the release. Worthley reported the study’s 1-year findings during a presentation at EuroPCR in Paris.

At the American Society of Hypertension Annual Scientific Meeting in mid-May, Vasilios Papademetriou, MD, presented 6-month data from the EnligHTN I trial.

After renal denervation, average office BP was reduced by –28 mm Hg/10 mm Hg at 1 month, –27 mm Hg/10 mm Hg at 3 months and –26 mm Hg/10 mm Hg at 6 months (P<.001 for all). Mean reductions in 24-hour ambulatory BP monitoring (baseline, 150 mm Hg/83 mm Hg) were –10 mm Hg/5 mm Hg at 1 month, –10 mm Hg/5 mm Hg at 3 months and –10 mm Hg/6 mm Hg  at 6 months (P<.001 for all). The percent of responders was 78% at 1 month, 80% at 3 months and 76% at 6 months, according to the study abstract.

Effective BP reduction was observed in all subgroups of patients, including those with type 2 diabetes, CAD, sleep apnea and elevated BMI. Pearson correlation analysis revealed a strong association between systolic BP response at 6 months and baseline BP (P<.0001) and baseline heart rate (P=.04), according to the abstract.

The researchers reported no clinically significant changes in serum creatinine or estimated glomerular filtration rate and no serious or life-threatening periprocedural complications.

“We concluded that data through 6 months demonstrate that the EnligHTN ablation system is safe and effective in the treatment of patients with drug-resistant hypertension,” Papademetriou and colleagues concluded.

In the EnligHTN I trial population, an average of 7.7 lesions were created in the right renal artery and 7.4 in the left renal artery. Median procedure time was 30 minutes, according to the study abstract.

Patients in this trial will be followed for 2 years after the procedure.

For more information:

Papademetriou V. LB-OR-03. Presented at: American Society of Hypertension Annual Scientific Meeting; May 15-18, 2013; San Francisco.

Worthley S. Renal denervation: Novel approaches and first-in-man results. Presented at: EuroPCR; May 21-24, 2013; Paris.

Disclosure: The EnligHTN I trial was sponsored by St. Jude Medical.